NCT00274599已完成4 期
A Prospective, Randomised, Open-Label, Blinded-Endpoint, Parallel Group, Multicentre, Forced-Titration, 14-Week Treatment Study Comparing MICARDIS® (Telmisartan 40-80-80 mg, QD) and ALTACE® (Ramipril 2.5-5-10 mg, QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 812
- 试验地点
- 75
- 主要终点
- Change from baseline in the last 6-hr mean DBP & SBP as measured by ABPM at the end of and 8-wk treatment period (T80 vs R5 mg) and 14-wk treatment period (T80 vs R10 mg)
研究概览
简要总结
Demonstrate that telmisartan 80mg was at least as effective and possibly superior to ramipril 5mg & 10mg in lowering mean ambulatory DBP and SBP during the last 6 hrs of the 24-hr dosing interval in mild-to-moderate hypertensives at the end of 8 and 14 week treatment phases.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to provide written informed consent in accordance with Good Clinical Practice (GCP) and local legislation.
- •Mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of ≥95 mmHg and ≤109 mmHg, measured by manual cuff sphygmomanometer at Visit
- •Age 18 years or older (or 19 years if dictated by local State/Province policies).
- •Ability to stop any current antihypertensive therapy without risk to the patient (investigator's discretion).
- •24-hour mean DBP of ≥85 mmHg at Visit 3 as measured by Ambulatory Blood Pressure Monitoring (ABPM).
排除标准
- •Pre-menopausal women (last menstruation ≤1 year prior to signing informed consent) who:
- •were not surgically sterile; or
- •were nursing, or
- •were of childbearing potential and were NOT practicing acceptable methods of birth control, or did NOT plan to continue practicing an acceptable method throughout the study. Acceptable methods of birth control included IUD, oral, implantable or injectable contraceptives. No exceptions were made.
- •Night shift workers who routinely slept during the daytime and whose work hours included midnight to 4:00 a.m.
- •Mean seated SBP ≥180 mmHg or mean seated DBP ≥110 mmHg during any visit of the placebo run-in period.
- •Known or suspected secondary hypertension (e.g., phaeochromocytoma).
- •Hepatic and/or renal dysfunction as defined by the following laboratory parameters:
- •Serum Glutamate-Oxaloacetate-Transaminase (Aspartate Aminotransferase) (SGOT (AST)) or Serum Glutamate-Pyruvate-Transaminase (Alanine Aminotransferase) (SGPT (ALT)) >2 times the upper limit of normal range, or
- •Serum creatinine >2.3 mg/dL (or >203 μmol/l).
- •Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant patients or patients with only one kidney.
- •Clinically relevant sodium depletion, hypokalaemia or hyperkalaemia.
- •Uncorrected volume depletion.
- •Further exclusion criteria apply
结局指标
主要结局
Change from baseline in the last 6-hr mean DBP & SBP as measured by ABPM at the end of and 8-wk treatment period (T80 vs R5 mg) and 14-wk treatment period (T80 vs R10 mg)
时间窗: Up to week 14
次要结局
- Change from baseline in last 6-hr ABPM mean for: pulse pressure; DBP, SBP and PP; DBP/SBP/PP in the morning, daytime and nighttime periods of the 24-hr dosing interval; Change from baseline in mean, seated, trough DBP & SBP measured by manual cuff(Up to week 14)
研究者
研究点 (75)
Loading locations...
相似试验
已完成
1 期
Bioequivalence of Telmisartan/g Ramipril Fixed Dose Combination Compared With the Monocomponents Telmisartan and Ramipril (Two Different Formulations) Given Concomitantly to Healthy Male and Female VolunteersHealthyNCT02214992Boehringer Ingelheim84
已完成
1 期
Bioequivalence Study of Telmisartan Between T80/A5/H12.5 mg FDC Tablet and T80/A5 mg Tab and H12.5 mg Tab Concomitant UseHealthyNCT02121535Boehringer Ingelheim72
已完成
4 期
Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive PatientsHypertensionNCT02172586Boehringer Ingelheim363
已完成
4 期
Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPMHypertensionNCT00274612Boehringer Ingelheim801
已完成
1 期
Bioequivalence of Telmisartan / Ramipril Fixed Dose Combination Compared With the Monocomponents Given Concomitantly to Healthy Male and Female VolunteersHealthyNCT02214979Boehringer Ingelheim84